The VA has 10 facilities identified for psychedelic therapies and no timeline. Plus the withdrawn FDA nomination, Helus’s Phase 3 psilocin data, and Oregon’s service-center challenge.
A senior Veterans Health Administration adviser told a House Veterans’ Affairs subcommittee on Nov. 18 that veterans’ demand for psychedelic therapies will exceed what the VA can supply, The Microdose reported. His written testimony says the VA has identified 10 facilities as early implementers, educators or sites in training and will begin clinical use only after all regulatory approvals. The White House withdrew Heidi Overton’s nomination to lead the FDA on Nov. 17, the day before a scheduled Senate committee vote. Helus Pharma said its deuterated psilocin drug met the primary endpoint of its first Phase 3 depression trial and reported three treatment-related serious adverse events. A federal judge in Oregon heard a disability-law challenge to the state’s service-center requirement for licensed psilocybin services. Short items cover a Utah psilocybin church case, Definium’s drug-application plan and DEA medical marijuana registrations.
VA Identifies 10 Facilities for Psychedelic Therapies, Gives No Timeline
Veterans Health Administration senior adviser Andrew Gradison told the House Veterans’ Affairs Subcommittee on Health, “Our demand for these treatments will exceed our ability to supply them,” according to The Microdose.
In written testimony for a Nov. 18 oversight hearing, Gradison, who advises the under secretary for health, wrote that the VA has identified 10 facilities with “the expertise, physical space, and operational capacity needed to serve as early implementers, educators, or sites-in-training” and “will only proceed with clinical implementation after completion of all regulatory approvals.” The VA had 21 active clinical research studies of psychedelic treatments as of September, including studies of MDMA, psilocybin, DMT and LSD, he wrote.
The committee listed the session, “Psychedelic-Assisted Therapies for Veterans: The Path Forward,” as an oversight hearing. Gradison’s testimony cites the five-year memorandum of understanding the VA and HHS signed July 13 on psychedelic research and the psilocybin depression trial the VA launched Aug. 5. He also wrote that the VA strongly discourages self-medicating, including with psychedelics.
University of Iowa assistant professor of psychiatry Mark Niciu, on the second panel, said implementation “might still take months to years” after FDA approval, The Microdose reported.
Subcommittee ranking member Julia Brownley (D-Calif.) said, “It will be critical for VA to carefully develop criteria for any provider of psychedelic-assisted treatments to be able to join its community care network,” Marijuana Moment reported. Disabled American Veterans, the Veterans of Foreign Wars, the Special Forces Foundation, Mindbloom and the American Psychiatric Association submitted written statements for the record.
Psychedelics Today (PT) reported Oct. 27 that the VA had chosen 10 sites and expected reaching 1,000 patients in the first year to be a challenge. Gradison’s written testimony gives no timeline, cost or number of veterans the 10 facilities could treat. The session was an oversight hearing, not action on a bill, and it did not change what treatments the VA can offer.
White House Withdraws Overton’s FDA Nomination Before Senate Committee Vote
The White House withdrew Heidi Overton’s nomination as FDA commissioner on Nov. 17, ABC News reported, citing an official. The withdrawal leaves the FDA under a temporary chief and without a nominee, days after Compass Pathways said it had finished submitting its psilocybin application to the agency. The Senate Health, Education, Labor and Pensions (HELP) Committee had been slated to vote Nov. 18 on whether to recommend her to the full Senate, and the White House dropped the bid for lack of congressional support, Bloomberg reported, citing Axios. Committee Chair Bill Cassidy (R-La.) said in a statement on social media, “I believe she would have had the votes to pass out of committee and pass the full Senate,” according to ABC News. Cassidy said anti-abortion Republican senators had sought final assurances from the administration on abortion-related policies, and that the administration withdrew Overton instead of giving them, ABC News reported.
Bloomberg reported that Kyle Diamantas, who previously headed the FDA’s food center, is leading the agency on a temporary basis. The outlet also reported that Calley Means, who recently left his job as a top adviser to HHS Secretary Robert F. Kennedy Jr., had claimed Overton opposed Kennedy’s policy goals on pesticides, food policy, vaccines and psychedelic treatments. It is unclear whether the White House could advance a replacement nomination before Democrats take control of the Senate in January, Bloomberg reported.
PT reported Nov. 13 that the committee vote had been scheduled for Nov. 18. That briefing also reported that Compass Pathways had completed submission of its psilocybin application to the FDA and, citing Psychedelic Alpha, that Usona Institute had done the same. As of Nov. 19, the White House had not announced a new nominee.
Helus Psilocin Drug Meets Phase 3 Endpoint, With Three Treatment-Related Serious Adverse Events
Helus Pharma said Nov. 16 that HLP003, a deuterated psilocin drug given alongside existing antidepressants, met the primary endpoint of its Phase 3 APPROACH study in 222 adults with moderate to severe major depressive disorder. Scores on the Montgomery-Åsberg Depression Rating Scale fell 19.5 points on HLP003 and 11.9 points on placebo at week 6, a difference of 7.6 points. At week 12 the reductions were 16.9 and 9.9 points.
The company reported three treatment-related serious adverse events. On an investor call, Helus said they were two cases of depression and one suicide attempt, BioSpace reported. BioSpace reported that Chief Medical Officer Amir Inamdar said the suicide attempt occurred 55 days after the second dose in a participant who did not respond to treatment. HLP003 holds FDA Breakthrough Therapy designation. APPROACH is the first of three studies in the company’s Phase 3 program, and Helus said it expects topline results from a second pivotal trial, EMBRACE, in the fourth quarter of 2027.
HLP003 is investigational. The Phase 3 results are not an application or an FDA approval, and the Nov. 16 release gives no date for a new drug application.
Federal Judge Hears Disability-Law Challenge to Oregon’s Service-Center Rule for Psilocybin
U.S. District Judge Mustafa Kasubhai heard arguments Nov. 16 on whether federal law prohibiting discrimination against people with disabilities requires Oregon to let licensed facilitators provide psilocybin services in the homes of people who cannot travel to a service center, Lookout Eugene-Springfield reported. Psilocybin facilitators filed the challenge in June 2024.
An Oregon Department of Justice attorney argued that state law allows licensed facilitators to administer psilocybin only at regulated facilities, said the facilitators had not shown they sought a “reasonable modification,” and raised safety concerns about in-home sessions. Kasubhai said he would rule within about 60 days, according to the outlet. The case concerns where Oregon’s licensed psilocybin services may take place; psilocybin’s federal status would remain unchanged.
Also This Week
Catch-up, Nov. 9 to Nov. 11
Utah psilocybin church. The U.S. Court of Appeals for the Tenth Circuit declined to rehear its Oct. 5 ruling that the district court should have abstained from blocking the state criminal prosecution of the founder of the psilocybin church Singularism. In a two-page order issued Nov. 9, the court denied Singularism’s request for an en banc rehearing, Law360 reported Nov. 10. The Oct. 5 ruling expressed no opinion on a separate injunction, based on Utah’s religious freedom law, that the state had not appealed.
Definium. Definium Therapeutics said Nov. 9 it is on track to submit a new drug application for DT120 ODT, an orally disintegrating LSD tablet, in the first half of 2027. Separately, the company said it received FDA Breakthrough Therapy designation for DT120 ODT in major depressive disorder.
DEA and medical marijuana. The DEA is rejecting federal registration applications from medical marijuana businesses in at least six states and Washington, D.C., and has sent orders to show cause to some of them, Marijuana Moment reported Nov. 11, citing industry sources and the text of some orders shared with the outlet. The businesses had sought registration under the attorney general’s April order moving state-licensed medical marijuana products to Schedule III.
The FDA’s comment period on ibogaine trial design closes Nov. 20, and comments on the DEA’s proposed 2027 production quotas, docket DEA-1730P, are due Dec. 10.
Psychedelics Today editors selected and edited the items in this briefing, using AI tools to assist with research and drafting. Joe Moore checked each item against its sources before publication. Read our editorial standards.
